Texas Capital Bank Wealth Management Services Inc Raises Stake in Danaher Co. (NYSE:DHR)

Texas Capital Bank Wealth Management Services Inc raised its holdings in shares of Danaher Co. (NYSE:DHR) by 2.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,138 shares of the conglomerate’s stock after purchasing an additional 628 shares during the period. Texas Capital Bank Wealth Management Services Inc’s holdings in Danaher were worth $8,030,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Gilbert & Cook Inc. raised its stake in shares of Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after purchasing an additional 86 shares during the last quarter. Accretive Wealth Partners LLC lifted its stake in Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after acquiring an additional 414 shares during the period. Gryphon Financial Partners LLC boosted its holdings in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after acquiring an additional 468 shares during the last quarter. Catalytic Wealth RIA LLC bought a new stake in shares of Danaher in the fourth quarter worth approximately $209,000. Finally, Avestar Capital LLC lifted its position in Danaher by 30.5% during the fourth quarter. Avestar Capital LLC now owns 1,832 shares of the conglomerate’s stock valued at $424,000 after purchasing an additional 428 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Down 0.5 %

NYSE DHR opened at $275.47 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The stock’s 50 day moving average is $270.23 and its 200 day moving average is $257.84. The stock has a market cap of $204.04 billion, a PE ratio of 46.69, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on DHR. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Evercore ISI reduced their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. The Goldman Sachs Group raised their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. TD Cowen increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.